Key facts
- Arda Therapeutics’s last known valuation is $80.0M.
- It has raised $50.8M across 2 recorded rounds; the latest was Early Stage VC ($43.3M) in Sep 2024.
- Notable investors include Alumni Ventures, Andreessen Horowitz, Mana Ventures, Gaingels, GV — 20 tracked in total.
- Arda Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Oct 2024 ($43.3M sold to 17 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Arda Therapeutics
Funding rounds
2 roundsAbout Arda Therapeutics
Developer of transformative therapeutics designed to remove pathological cells, which are the root causes of chronic diseases. The company first uses single-cell data from patients to identify which cells to target and how to target them, and then designs therapeutics to remove the entire pathological network that is the entire cell, enabling patients to get cured without affecting any cell other than their pathological cells.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Founded
- 2021
- Employees
- 10
- Website
- ardatx.com/
- Ownership
- Privately Held (backing)
Arda Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arda Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arda Therapeutics in its N-PORT filings yet. We sweep new filings monthly.